National Institute for Health and Care Excellence , NICE (Abkürzung)

National Institute for Health and Care Excellence in the UK

National Institute for Health and Care Excellence (NICE) has issued guidelines for the recognition and treatment of neonatal jaundice in the United Kingdom.

In the UK, the National Institute for Health and Care Excellence (NICE) calculated the cost of belimumab at £61,200 per quality adjusted life year (QALY).

Following the Health and Social Care Act 2012, NICE was renamed the National Institute for Health and Care Excellence on 1 April 2013 and changed from a special health authority to a non-departmental public body.

The National Institute for Health and Care Excellence (NICE) is a non-departmental public body of the Department of Health in the United Kingdom, serving both the English NHS and the Welsh NHS.

NICE, the National Institute for Health and Care Excellence, has said that those likely to be admitted or referred to a hospital are individuals who are either immunosuppressed, pregnant, an infant who is 1 year of age or younger, or a person who has developed a serious complication from measles infection, such as pneumonia.